This inventor holds 1 USPTO granted patent. Top assignee: Academia Sinica. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Innovations by Chien-Sheng Lu in IgE-Mediated Disease Treatment.
Introduction
Chien-Sheng Lu is a prominent inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of immunology, particularly in the development of antibodies for treating IgE-mediated diseases. His work is recognized for its potential impact on therapeutic strategies for allergic conditions.
Latest Patents
Chien-Sheng Lu holds a patent for "Antibodies specific to a novel epitope on CεMX of human membrane-bound IgE and uses thereof in treating IgE-mediated diseases." This patent describes anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, specifically the sequence SVPHPRCHCGAGRA (SEQ ID NO: 4). The implications of this invention are significant for the treatment of various IgE-mediated diseases.
Career Highlights
Chien-Sheng Lu is affiliated with Academia Sinica, a leading research institution in Taiwan. His work at this prestigious institution has allowed him to focus on innovative research that bridges the gap between basic science and clinical applications. His dedication to advancing medical science is evident in his research endeavors.
Collaborations
Chien-Sheng Lu has collaborated with notable colleagues, including Tse Wen Chang and Chien-Jen Lin. These collaborations have fostered a productive research environment, leading to advancements in the understanding and treatment of allergic diseases.
Conclusion
Chien-Sheng Lu's contributions to the field of immunology, particularly through his patent on anti-IgE antibodies, highlight his role as an innovator in medical research. His work has the potential to transform treatment options for individuals suffering from IgE-mediated diseases.